Developer docs
API playgroundTry for free, no card

Search company profiles

Numab

Full company profile

uuid00008h8

Namestring
Numab
Legal namestring
Numab Therapeutics AG
Websiteurl
numab.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Numab Therapeutics AG is a privately held Swiss clinical-stage biopharmaceutical company founded in 2011 and headquartered in Horgen, Switzerland, that develops multi-specific antibody-based therapeutics for severe inflammatory diseases and oncology. The company's core technology consists of two proprietary platforms: λ-Cap™, a stability-conferring Fv acceptor scaffold, and MATCH™ (Multispecific Antibody-based Therapeutics by Cognate Heterodimerization), a modular plug-and-play scaffolding system that can incorporate up to six binding specificities in a single molecule. Numab supplements its discovery engine with an ultra-high throughput rabbit antibody discovery platform that characterizes full antibody repertoires in days, combined with structure-guided engineering for half-life extension and reduced anti-drug antibody reactivity.

Numab operates a partnership-driven business model rather than commercializing products directly. Revenue derives from licensing agreements and co-development deals with pharmaceutical partners, including upfront payments, milestone payments, and royalties. The company retains certain regional co-development rights and selectively spins out pipeline assets into subsidiaries that can be acquired outright. A landmark $1.25 billion acquisition of subsidiary Yellow Jersey Therapeutics (holding NM26) by Johnson & Johnson in May 2024 validated the platform commercially. Active partnerships span Boehringer Ingelheim (oncology and geographic atrophy), Kaken Pharmaceutical (NM81 for IBD in Asian territories), Ono Pharmaceutical (multiple immuno-oncology programs worth up to CHF 260 million in potential milestones), CStone, 3SBio/Sunshine Guojian, Eisai, and Mage Biologics.

Numab's pipeline includes clinical-stage programs such as NM21-1480 (tri-specific PD-L1/4-1BB/HSA for oncology), NM32 (ROR1 T-cell engager, Phase 1 initiated October 2024), and NM81 (multispecific for IBD, partnered with Kaken), alongside partnered programs ND059 and ND047 with Boehringer Ingelheim. The company is led by newly appointed CEO Barbara Angehrn Pavik (effective September 2025), who succeeded founder David Urech, with a board chaired by Carlo Incerti (Forbion Operating Partner). Numab is backed by institutional investors including Novo Holdings, HBM Partners, Forbion, Cormorant, BVF Partners, RTW Investments, and BlackRock, having raised CHF 180 million in total Series C financing completed in January 2025.

Short descriptiontext

Numab Therapeutics AG is a Swiss clinical-stage biopharmaceutical company that develops proprietary multi-specific antibody therapeutics for inflammatory diseases and oncology using its λ-Cap™ and MATCH™ platforms, partnering with global pharmaceutical companies for late-stage development and commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHorgen, Switzerland
HQ citystring
Horgen
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multispecific antibody therapeutics, immuno-oncology drug development, antibody discovery platform, biopharmaceutical licensing, clinical-stage biotech
Industry2 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Multispecific Antibody Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing and Co-development Agreements
TypeLicensing Royalties
Description

Numab enters into licensing and co-development agreements with pharmaceutical partners where partners receive rights to develop and commercialize candidates in exchange for upfront payments, milestone payments, and royalty payments on net sales. Examples include Kaken Pharmaceutical (NM81 for IBD in Asian territories), Boehringer Ingelheim (ND059 for geographic atrophy, ND047 for GI cancer), and multiple historical partnerships.

numab.com
2M&A / Asset Acquisition
TypeLicensing Royalties
Description

Numab generates significant value through acquisition of its subsidiary companies and pipeline assets. Johnson & Johnson's $1.25 billion acquisition of Yellow Jersey Therapeutics (holding NM26 rights for atopic dermatitis) in 2024 represents a major exit event.

numab.com
3Research Grants
TypeProfessional Services
Description

The company has received non-dilutive funding from Swiss government sources including CTI (Commission for Technology and Innovation) grants for research activities.

numab.com
4Equity Financing
TypeSubscription Recurring
Description

Numab has raised multiple equity rounds including Series B (CHF 22M in 2020), Series C (CHF 100M in 2021), and Series C extension (CHF 50M in 2025) bringing total Series C to CHF 180M. Funding led by Novo Holdings, HBM Partners, Forbion, and other institutional investors.

startupticker.ch
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Numab Therapeutics AG is a clinical-stage biopharmaceutical company developing multi-specific antibody-based immunotherapies for severe inflammatory diseases and cancer. The company applies its proprietary λ-Cap™ and MATCH™ platforms to engineer bi- and tri-specific antibody candidates with tailored pharmacokinetics, advancing them through preclinical and clinical development. Numab monetizes its pipeline primarily through licensing and co-development agreements with large pharmaceutical partners, granting development and commercialization rights in exchange for upfront payments, milestones, and royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • $1.25 billion acquisition value for NM26 (atopic dermatitis candidate)
+2 more records
Product overview1 text field

Numab Therapeutics AG is a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for inflammation and cancer. The company's proprietary plug-and-play platform combines two core technologies: λ-Cap™ (a modular scaffolding technology providing unprecedented stability) and MATCH™ (Multispecific Antibody-based Therapeutics by Cognate Heterodimerization). These platforms enable the repeatable generation of mono- or multispecific antibody fragment-based therapeutics with tailored pharmacokinetic properties. Numab's proprietary pipeline includes programs such as NM26 (bispecific for atopic dermatitis), NM32 (T-cell engager for solid tumors), NM81 (multispecific for IBD), and ND021/NM21-1480 (trispecific for immuno-oncology targeting PD-L1, 4-1BB, and Serum Albumin). The company also advances partnered programs with Boehringer Ingelheim, Kaken Pharmaceutical, Ono Pharmaceutical, and others, while some programs have been successfully out-licensed (NM26 acquired by Johnson & Johnson) or partnered globally (NM09 with Mage Biologics, NM28 with 3SBio/Sunshine Guojian).

Product and service1 record
1NM26 (NM26-2198)
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Kaken Pharmaceutical
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-13
Description

Licensing and co-development agreement for NM81, a multispecific antibody for inflammatory bowel disease (IBD). Kaken exercised option to acquire rights for select Asian territories and commits to funding global development into clinical trials. Both companies collaboratively advance the drug through clinical trials with Kaken funding development. Represents expansion of earlier 2017 collaboration.

biospace.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-05-28
Description

J&J acquired Numab's wholly-owned subsidiary Yellow Jersey Therapeutics, including rights to NM26 (bi-specific antibody for atopic dermatitis), for $1.25 billion. J&J gained full rights to develop, manufacture and commercialize globally.

3Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-07-07
Description

Research collaboration and worldwide licensing agreement for multi-specific antibody therapeutics targeting difficult-to-treat lung and gastrointestinal cancers and geographic atrophy (GA). Boehringer Ingelheim brings expertise in breakthrough therapy development. Collaboration includes multiple projects with ND059 (retinal diseases) and ND047 (T-cell engager for GI cancer) in the pipeline. Boehringer advanced multiple programs into preclinical development, triggering milestone payments to Numab.

globenewswire.com
4Ono Pharmaceutical
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-03-30
Description

Multiple research and option agreements for multi-specific antibody candidates in immuno-oncology. Ono has option to acquire exclusive rights to develop and commercialize candidates. Agreements include potential CHF 260 million in upfront and milestone payments plus tiered royalties. Third collaboration agreement announced in 2024 for NM49 (tumor associated macrophage phagocytosis program).

numab.com
53SBio / Sunshine Guojian
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-12-12
Description

Partnership for development and commercialization of novel multi-specific cancer antibodies. Sunshine Guojian invested CHF 15M in Numab's Series B. Exercise of option for exclusive regional license for NM28, a best-in-class bivalent mesothelin-targeting CD3 T cell engager.

numab.com
6Eisai
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-10-01
Description

Global research and option agreement to discover and develop novel multi-specific antibody immunotherapies for cancer using Numab's MATCH™ platform.

numab.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-05-02
Description

Exclusive regional licensing agreement for ND021 (NM21-1480), a tri-specific antibody targeting PD-L1, 4-1BB, and HSA for cancer treatment. CStone acquired rights for development and commercialization in Greater China and Singapore.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-03-05
Description

License agreement for ND016 (autoimmune disorders) with Intarcia receiving worldwide rights. Potential payments of up to CHF 70 million plus double-digit tiered royalties. Collaboration initiated in 2015 for antibody-based therapeutics addressing diabetes, obesity, and autoimmune indications.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2015-06-09
Description

Exclusive global licensing agreement to develop and commercialize new antibody-based therapies targeting TNF-α for inflammatory bowel disease (IBD).

10Swiss Commission for Technology and Innovation (CTI)
Strategic tierMinorTypeOthersAnnounced on2012-03-06
Description

Swiss government research grant of CHF 895,000 supporting research on antibody-based approaches for therapy of ion channel-driven health disorders, conducted in collaboration with Zürich University of Applied Sciences (ZHAW). CTI Start-up Label awarded in 2012.

numab.com
11Mage Biologics
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

License agreement for NM09, an anti-TNF antibody fragment for inflammatory bowel disease, to Mage Biologics for development and commercialization of innovative formulations.

numab.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss clinical-stage biotech developing multi-specific DARPin-based therapeutics for oncology and infectious diseases. Directly comparable to Numab as a Switzerland-based, similarly-sized biotech using proprietary multi-specific protein scaffold technology to partner with large pharma.

TypeDirect peer
Description

Global leader in bispecific antibody therapeutics (DuoBody platform) and antibody drug conjugates. Closely comparable to Numab's multi-specific antibody platform approach, with broader pipeline and approved products including daratumumab.

TypeDirect peer
Description

Clinical-stage biotech with proprietary multispecific antibody platforms (Azymetric, EFECT) targeting oncology and inflammatory diseases. Direct competitor in multi-specific antibody engineering with similar partnership-driven business model.

TypeDirect peer
Description

Clinical-stage biotech with XmAb bispecific antibody platform and Fc engineering technologies, partnered with multiple large pharma companies. Directly comparable to Numab in multi-specific antibody platform approach and partnership model.

TypeEmerging player
Description

Clinical-stage biotech developing multi-domain biologic therapeutics for cancer and rare diseases. Comparable to Numab in multi-specific platform approach and partnership-driven development model.

TypeEmerging player
Description

Antibody discovery platform company partnering with pharma to identify fully human antibodies. Comparable to Numab's rabbit antibody discovery engine and platform-based business model, though focused on discovery rather than development.

TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies and antibody drug conjugates for cancer. Comparable to Numab in multi-specific antibody development and oncology focus.

TypeEmerging player
Description

Clinical-stage biotech developing bispecific antibodies for cancer, including NK cell engagers and T-cell engagers. Comparable to Numab in multi-specific antibody approach and oncology pipeline.

TypeEmerging player
Description

Swiss-based biotech developing antibody-based therapeutics and small molecule drug conjugates. Comparable to Numab in multi-specific antibody discovery, Swiss biotech location, and partnership model.

TypeBroad incumbent
Description

Developer of T-cell engagers using proprietary TriTAC platform for cancer, acquired by Merck in 2024. Comparable to Numab's T-cell engager programs (e.g., NM32 ROR1) and represents an example of platform value crystallization similar to the J&J/Numab deal.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Numab

Multispecific Antibody Therapeuticsnumab.com

Numab Therapeutics AG is a Swiss clinical-stage biopharmaceutical company that develops proprietary multi-specific antibody therapeutics for inflammatory diseases and oncology using its λ-Cap™ and MATCH™ platforms, partnering with global pharmaceutical companies for late-stage development and commercialization.

What Numab does

Numab Therapeutics AG is a privately held Swiss clinical-stage biopharmaceutical company founded in 2011 and headquartered in Horgen, Switzerland, that develops multi-specific antibody-based therapeutics for severe inflammatory diseases and oncology. The company's core technology consists of two proprietary platforms: λ-Cap™, a stability-conferring Fv acceptor scaffold, and MATCH™ (Multispecific Antibody-based Therapeutics by Cognate Heterodimerization), a modular plug-and-play scaffolding system that can incorporate up to six binding specificities in a single molecule. Numab supplements its discovery engine with an ultra-high throughput rabbit antibody discovery platform that characterizes full antibody repertoires in days, combined with structure-guided engineering for half-life extension and reduced anti-drug antibody reactivity.

Numab operates a partnership-driven business model rather than commercializing products directly. Revenue derives from licensing agreements and co-development deals with pharmaceutical partners, including upfront payments, milestone payments, and royalties. The company retains certain regional co-development rights and selectively spins out pipeline assets into subsidiaries that can be acquired outright. A landmark $1.25 billion acquisition of subsidiary Yellow Jersey Therapeutics (holding NM26) by Johnson & Johnson in May 2024 validated the platform commercially. Active partnerships span Boehringer Ingelheim (oncology and geographic atrophy), Kaken Pharmaceutical (NM81 for IBD in Asian territories), Ono Pharmaceutical (multiple immuno-oncology programs worth up to CHF 260 million in potential milestones), CStone, 3SBio/Sunshine Guojian, Eisai, and Mage Biologics.

Numab's pipeline includes clinical-stage programs such as NM21-1480 (tri-specific PD-L1/4-1BB/HSA for oncology), NM32 (ROR1 T-cell engager, Phase 1 initiated October 2024), and NM81 (multispecific for IBD, partnered with Kaken), alongside partnered programs ND059 and ND047 with Boehringer Ingelheim. The company is led by newly appointed CEO Barbara Angehrn Pavik (effective September 2025), who succeeded founder David Urech, with a board chaired by Carlo Incerti (Forbion Operating Partner). Numab is backed by institutional investors including Novo Holdings, HBM Partners, Forbion, Cormorant, BVF Partners, RTW Investments, and BlackRock, having raised CHF 180 million in total Series C financing completed in January 2025.

Numab firmographics

Firmographics
Name
Numab
Legal name
Numab Therapeutics AG
Website
https://numab.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
Numab Therapeutics AG is a Swiss clinical-stage biopharmaceutical company that develops proprietary multi-specific antibody therapeutics for inflammatory diseases and oncology using its λ-Cap™ and MATCH™ platforms, partnering with global pharmaceutical companies for late-stage development and commercialization.
Ownership category
akta.pro rank

Numab industry classification

Industry
Product category
Multispecific Antibody Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Multispecific antibody therapeutics
  • Immuno-oncology drug development
  • Antibody discovery platform
  • Biopharmaceutical licensing
  • Clinical-stage biotech

Where Numab is headquartered

Location

Headquarters

HQ city
Horgen
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Numab business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Co-development Agreements: Numab enters into licensing and co-development agreements with pharmaceutical partners where partners receive rights to develop and commercialize candidates in exchange for upfront payments, milestone payments, and royalty payments on net sales. Examples include Kaken Pharmaceutical (NM81 for IBD in Asian territories), Boehringer Ingelheim (ND059 for geographic atrophy, ND047 for GI cancer), and multiple historical partnerships.
  2. M&A / Asset Acquisition: Numab generates significant value through acquisition of its subsidiary companies and pipeline assets. Johnson & Johnson's $1.25 billion acquisition of Yellow Jersey Therapeutics (holding NM26 rights for atopic dermatitis) in 2024 represents a major exit event.
  3. Research Grants: The company has received non-dilutive funding from Swiss government sources including CTI (Commission for Technology and Innovation) grants for research activities.
  4. Equity Financing: Numab has raised multiple equity rounds including Series B (CHF 22M in 2020), Series C (CHF 100M in 2021), and Series C extension (CHF 50M in 2025) bringing total Series C to CHF 180M. Funding led by Novo Holdings, HBM Partners, Forbion, and other institutional investors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Numab product offering

Product offering

Core offering

Numab Therapeutics AG is a clinical-stage biopharmaceutical company developing multi-specific antibody-based immunotherapies for severe inflammatory diseases and cancer. The company applies its proprietary λ-Cap™ and MATCH™ platforms to engineer bi- and tri-specific antibody candidates with tailored pharmacokinetics, advancing them through preclinical and clinical development. Numab monetizes its pipeline primarily through licensing and co-development agreements with large pharmaceutical partners, granting development and commercialization rights in exchange for upfront payments, milestones, and royalties.

Product overview

Numab Therapeutics AG is a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for inflammation and cancer. The company's proprietary plug-and-play platform combines two core technologies: λ-Cap™ (a modular scaffolding technology providing unprecedented stability) and MATCH™ (Multispecific Antibody-based Therapeutics by Cognate Heterodimerization). These platforms enable the repeatable generation of mono- or multispecific antibody fragment-based therapeutics with tailored pharmacokinetic properties. Numab's proprietary pipeline includes programs such as NM26 (bispecific for atopic dermatitis), NM32 (T-cell engager for solid tumors), NM81 (multispecific for IBD), and ND021/NM21-1480 (trispecific for immuno-oncology targeting PD-L1, 4-1BB, and Serum Albumin). The company also advances partnered programs with Boehringer Ingelheim, Kaken Pharmaceutical, Ono Pharmaceutical, and others, while some programs have been successfully out-licensed (NM26 acquired by Johnson & Johnson) or partnered globally (NM09 with Mage Biologics, NM28 with 3SBio/Sunshine Guojian).

Differentiator

Problem solved

Functional benefit

Products and services

  • NM26 (NM26-2198)

Quantifiable outcome

  • $1.25 billion acquisition value for NM26 (atopic dermatitis candidate)
  • +2 more outcomes

Companies that use Numab

Customer profile

Segments3 records

Ideal customer profiles3 records

Numab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Numab partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

  • Kaken PharmaceuticalcoreStrategic or Co-development Partner · 13 November 2025Licensing and co-development agreement for NM81, a multispecific antibody for inflammatory bowel disease (IBD). Kaken exercised option to acquire rights for select Asian territories and commits to funding global development into clinical trials. Both companies collaboratively advance the drug through clinical trials with Kaken funding development. Represents expansion of earlier 2017 collaboration.
  • Johnson & JohnsonmajorStrategic or Co-development Partner · 28 May 2024J&J acquired Numab's wholly-owned subsidiary Yellow Jersey Therapeutics, including rights to NM26 (bi-specific antibody for atopic dermatitis), for $1.25 billion. J&J gained full rights to develop, manufacture and commercialize globally.
  • Boehringer IngelheimcoreStrategic or Co-development Partner · 7 July 2020Research collaboration and worldwide licensing agreement for multi-specific antibody therapeutics targeting difficult-to-treat lung and gastrointestinal cancers and geographic atrophy (GA). Boehringer Ingelheim brings expertise in breakthrough therapy development. Collaboration includes multiple projects with ND059 (retinal diseases) and ND047 (T-cell engager for GI cancer) in the pipeline. Boehringer advanced multiple programs into preclinical development, triggering milestone payments to Numab.
  • Ono PharmaceuticalcoreStrategic or Co-development Partner · 30 March 2020Multiple research and option agreements for multi-specific antibody candidates in immuno-oncology. Ono has option to acquire exclusive rights to develop and commercialize candidates. Agreements include potential CHF 260 million in upfront and milestone payments plus tiered royalties. Third collaboration agreement announced in 2024 for NM49 (tumor associated macrophage phagocytosis program).
  • 3SBio / Sunshine GuojianmajorStrategic or Co-development Partner · 12 December 2019Partnership for development and commercialization of novel multi-specific cancer antibodies. Sunshine Guojian invested CHF 15M in Numab's Series B. Exercise of option for exclusive regional license for NM28, a best-in-class bivalent mesothelin-targeting CD3 T cell engager.
  • EisaimajorStrategic or Co-development Partner · 1 October 2019Global research and option agreement to discover and develop novel multi-specific antibody immunotherapies for cancer using Numab's MATCH™ platform.
  • CStone PharmaceuticalsmajorStrategic or Co-development Partner · 2 May 2019Exclusive regional licensing agreement for ND021 (NM21-1480), a tri-specific antibody targeting PD-L1, 4-1BB, and HSA for cancer treatment. CStone acquired rights for development and commercialization in Greater China and Singapore.
  • Intarcia TherapeuticsmajorOEM/ Whitelabel/ Licensing Partner · 5 March 2019License agreement for ND016 (autoimmune disorders) with Intarcia receiving worldwide rights. Potential payments of up to CHF 70 million plus double-digit tiered royalties. Collaboration initiated in 2015 for antibody-based therapeutics addressing diabetes, obesity, and autoimmune indications.
  • Tillotts PharmaminorOEM/ Whitelabel/ Licensing Partner · 9 June 2015Exclusive global licensing agreement to develop and commercialize new antibody-based therapies targeting TNF-α for inflammatory bowel disease (IBD).
  • Swiss Commission for Technology and Innovation (CTI)minorOthers · 6 March 2012Swiss government research grant of CHF 895,000 supporting research on antibody-based approaches for therapy of ion channel-driven health disorders, conducted in collaboration with Zürich University of Applied Sciences (ZHAW). CTI Start-up Label awarded in 2012.
  • Mage BiologicsminorOEM/ Whitelabel/ Licensing PartnerLicense agreement for NM09, an anti-TNF antibody fragment for inflammatory bowel disease, to Mage Biologics for development and commercialization of innovative formulations.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Numab competitors and assessment

Company assessment

Direct peers

  • Molecular Partners: Swiss clinical-stage biotech developing multi-specific DARPin-based therapeutics for oncology and infectious diseases. Directly comparable to Numab as a Switzerland-based, similarly-sized biotech using proprietary multi-specific protein scaffold technology to partner with large pharma.
  • Genmab: Global leader in bispecific antibody therapeutics (DuoBody platform) and antibody drug conjugates. Closely comparable to Numab's multi-specific antibody platform approach, with broader pipeline and approved products including daratumumab.
  • Zymeworks: Clinical-stage biotech with proprietary multispecific antibody platforms (Azymetric, EFECT) targeting oncology and inflammatory diseases. Direct competitor in multi-specific antibody engineering with similar partnership-driven business model.
  • Xencor: Clinical-stage biotech with XmAb bispecific antibody platform and Fc engineering technologies, partnered with multiple large pharma companies. Directly comparable to Numab in multi-specific antibody platform approach and partnership model.
  • Macrogenics: Clinical-stage biotech developing bispecific antibodies and antibody drug conjugates for cancer. Comparable to Numab in multi-specific antibody development and oncology focus.

Emerging players

  • Inhibrx Biosciences: Clinical-stage biotech developing multi-domain biologic therapeutics for cancer and rare diseases. Comparable to Numab in multi-specific platform approach and partnership-driven development model.
  • Adimab: Antibody discovery platform company partnering with pharma to identify fully human antibodies. Comparable to Numab's rabbit antibody discovery engine and platform-based business model, though focused on discovery rather than development.
  • Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies for cancer, including NK cell engagers and T-cell engagers. Comparable to Numab in multi-specific antibody approach and oncology pipeline.
  • Philochem: Swiss-based biotech developing antibody-based therapeutics and small molecule drug conjugates. Comparable to Numab in multi-specific antibody discovery, Swiss biotech location, and partnership model.

Broad incumbents

  • Harpoon Therapeutics (Merck): Developer of T-cell engagers using proprietary TriTAC platform for cancer, acquired by Merck in 2024. Comparable to Numab's T-cell engager programs (e.g., NM32 ROR1) and represents an example of platform value crystallization similar to the J&J/Numab deal.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Numab social profiles

Digital presence

Numab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Numab leadership team

Management profile

Number of profiles

Profiles21 records

Numab funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Numab M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Numab

What does Numab do?

Numab Therapeutics AG is a clinical-stage biopharmaceutical company developing multi-specific antibody-based immunotherapies for severe inflammatory diseases and cancer. The company applies its proprietary λ-Cap™ and MATCH™ platforms to engineer bi- and tri-specific antibody candidates with tailored pharmacokinetics, advancing them through preclinical and clinical development. Numab monetizes its pipeline primarily through licensing and co-development agreements with large pharmaceutical partners, granting development and commercialization rights in exchange for upfront payments, milestones, and royalties.

Is Numab a public or private company?

Numab is a private company. It is classified as venture growth investor backed and is currently operating.

When was Numab founded?

Numab was founded in 2011. It employs 51 to 100 people.

Where is Numab based?

Numab is headquartered in Horgen, Switzerland, in the Europe region.

How does Numab make money?

Four revenue lines are on record. Licensing and Co-development Agreements are the primary driver. The others are M&A / Asset Acquisition, research Grants and equity Financing.

Who are Numab's main competitors?

Direct peers on record are Molecular Partners, Genmab, Zymeworks, Xencor and Macrogenics. Emerging players are Inhibrx Biosciences, Adimab, Compass Therapeutics and Philochem. Harpoon Therapeutics (Merck) is listed as a broad incumbent.

Does Numab have an API?

No public API is recorded for Numab.

What industry is Numab in?

Numab's product category is Multispecific Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterNumab Therapeutics appoints Rajesh Chopra as CSONumab Therapeutics appointed Rajesh Chopra as chief scientific officer. The company is advancing NM81, a trispecific antibody for inflammatory bowel disease, and other programs in immunology and oncology.pharmaphorumJ&J abandons trial of atopic dermatitis drugJohnson & Johnson has discontinued a phase 2 trial of its pipeline candidate JNJ-5939 for atopic dermatitis after it failed to meet the company's "high-bar efficacy" threshold in the DUPLEX-AD proof-of-concept study, though the drug was well tolerated. The bispecific antibody, acquired from Swiss biotech Numab Therapeutics in a $1.25 billion all-cash deal completed in 2024, had been positioned as a potential first-in-class therapy targeting IL-4 and IL-31 receptors. Since JNJ-5939 is not enrolled in any other clinical trials for additional indications, the discontinuation effectively ends the programme, though J&J says it remains committed to advancing other atopic dermatitis candidates in its pipeline.BioWorldJ&J’s phase IIb AD bispecific washes up on Jersey shoreJohnson & Johnson's bispecific antibody targeting IL-4Ra and IL-31 for atopic dermatitis has failed in a Phase IIb trial, representing a significant setback for the company's dermatology pipeline. The product was acquired just last year when J&J paid $1.25 billion to bring it aboard through the acquisition of Yellow Jersey Therapeutics, a wholly owned subsidiary of Numab Therapeutics AG. The failure raises questions about the viability of the dual-receptor targeting strategy for AD treatment.startupticker.chRegulatory approval and a milestone payment for Swiss biotechsThe European Commission granted orphan designation to Memo Therapeutics' potravitug, a BK polyomavirus-neutralizing antibody for kidney transplant recipients, providing 10 years of market exclusivity, waived EMA fees, and protocol assistance. Numab Therapeutics triggered a milestone payment from Boehringer Ingelheim after achieving agreed development targets, with the pharma partner advancing two Numab programs into preclinical development for wet age-related macular degeneration and difficult-to-treat cancers. Memo plans to advance potravitug into Phase III clinical development in 2026.GlobeNewswireNumab Therapeutics Achieves Milestone in Second Collaboration Project with Boehringer IngelheimNumab Therapeutics announced that Boehringer Ingelheim has advanced a novel multi-specific antibody for wet age-related macular degeneration (AMD) into preclinical development, triggering a milestone payment to Numab. This represents the second project advancement under a 2020 worldwide research and licensing collaboration that also covers therapies for difficult-to-treat lung and gastrointestinal cancers. The milestone validates Numab's multi-specific antibody platform and underscores the continued success of the partnership with the global pharmaceutical company.TipranksPhysiomics Secures New Contract with Numab Therapeutics for Antibody DevelopmentPhysiomics plc has secured a new contract with Numab Therapeutics AG to support pre-clinical development of a multi-specific antibody for autoimmune diseases. The collaboration will involve developing a mechanistic PK/PD model to enhance understanding of the drug's behavior and inform dosing decisions for preclinical and clinical studies. This project reinforces Physiomics' role in advancing therapeutic antibody pipelines for both oncology and autoimmune indications.BioSpaceNumab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD)Numab Therapeutics and Kaken Pharmaceutical announced a strategic licensing and co-development agreement for NM81, a first-in-class multispecific antibody for inflammatory bowel disease, with Kaken acquiring commercial rights for select Asian territories. Under the agreement, both companies will jointly advance NM81 through clinical proof of concept, with Kaken funding preclinical and clinical development costs. The partnership builds on a research collaboration initiated in November 2024 and combines Kaken's development capabilities with Numab's multispecific antibody technology platforms.GlobeNewswireNumab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD)Numab Therapeutics AG, a Swiss biotechnology company, and Kaken Pharmaceutical Co., Ltd., a Japanese pharmaceutical company, have announced a strategic licensing and co-development agreement for NM81, a first-in-class multispecific antibody for inflammatory bowel disease. Under the agreement, Kaken will fund preclinical and clinical development while jointly advancing the drug through clinical proof of concept, with commercial rights granted for certain Asian territories. The partnership builds on a research collaboration established in November 2024, combining Numab's multispecific antibody technology platforms with Kaken's development capabilities.